Skip to main content

Advertisement

SpringerLink
Log in

Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy

  • Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors)
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

The prevalence of diabetes is growing at epidemic rates in the USA. Diabetic retinopathy develops in a large proportion of patients and is a leading cause of blindness worldwide. Systemic management of diabetic retinopathy has included glycemic, hypertension, and lipid control. Local ophthalmic treatment in the form of focal/grid or panretinal laser photocoagulation has been shown to prevent vision loss in diabetic edema and proliferative diabetic retinopathy, respectively. The introduction of anti-vascular endothelial growth factor for diabetic macular edema and retinopathy has provided clinicians with improved clinical outcomes with potentially less damaging effects than laser.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376(9735):124–36.

    Article  PubMed  Google Scholar 

  2. Senger DRCD, Perruzzi CA, Alsup D, Nelson R, Leimgruber R, Feder J, et al. Purification of a vascular permeability factor (VPF) from tumor cell conditioned medium. Fed Proc. 1987;46:2102.

    Google Scholar 

  3. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029–39.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306–9.

    Article  CAS  PubMed  Google Scholar 

  5. Miller JW. VEGF: from discovery to therapy: the Champalimaud Award Lecture. Transl Vision Sci Technol. 2016;5(2):9.

    Article  Google Scholar 

  6. Adamis AP, Miller JW, Bernal MT, D’Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445–50.

    Article  CAS  PubMed  Google Scholar 

  7. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480–7.

    Article  CAS  PubMed  Google Scholar 

  8. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98(5 Suppl):786–806.

  9. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98(5 Suppl):823–833.

  10. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98(5 Suppl):766–785.

  11. Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K, Hori S: Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefe’s Arch Clin Exp Ophthalmol = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2005, 243(1):3–8.

  12. Selim KM, Sahan D, Muhittin T, Osman C, Mustafa O. Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy. Indian J Ophthalmol. 2010;58(5):375–9.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Abu-El-Asrar AM, Dralands L, Missotten L, Al-Jadaan IA, Geboes K. Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci. 2004;45(8):2760–6.

    Article  PubMed  Google Scholar 

  14. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102(4):783–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ola MS, Alhomida AS. Neurodegeneration in diabetic retina and its potential drug targets. Curr Neuropharmacol. 2014;12(4):380–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ng JS, Bearse Jr MA, Schneck ME, Barez S, Adams AJ. Local diabetic retinopathy prediction by multifocal ERG delays over 3 years. Invest Ophthalmol Vis Sci. 2008;49(4):1622–8.

    Article  PubMed  Google Scholar 

  17. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615–25.

    Article  CAS  PubMed  Google Scholar 

  18. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2003;22(6):721–48.

    Article  CAS  PubMed  Google Scholar 

  19. Writing Team for the Diabetes C, Complications Trial/Epidemiology of Diabetes I, Complications Research G. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287(19):2563–9. Large prospective study showing benefits of systemic control of diabetes on retinopathy.

    Article  Google Scholar 

  20. • King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. British J Clin Pharmacol. 1999;48(5):643–8. Large prospective study showing benefits of systemic control of diabetes on retinopathy.

    Article  CAS  Google Scholar 

  21. Group AS, Group AES, Chew EY, Ambrosius WT, Davis MD, Danis RP, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233–44.

    Article  Google Scholar 

  22. Zehetner C, Kirchmair R, Kralinger M, Kieselbach G. Correlation of vascular endothelial growth factor plasma levels and glycemic control in patients with diabetic retinopathy. Acta Ophthalmol. 2013;91(6):e470–473.

    Article  CAS  PubMed  Google Scholar 

  23. Mateo-Gavira I, Vilchez-Lopez FJ, Garcia-Palacios MV, Carral-San Laureano F, Visiedo-Garcia FM, Aguilar-Diosdado M: Early blood pressure alterations are associated with pro-inflammatory markers in type 1 diabetes mellitus. J Hum Hypertens 2016.

  24. Zorena K, Mysliwska J, Mysliwiec M, Rybarczyk-Kapturska K, Malinowska E, Wisniewski P, et al. Association between vascular endothelial growth factor and hypertension in children and adolescents type I diabetes mellitus. J Hum Hypertens. 2010;24(11):755–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, Bouter LM, et al. Blood pressure, lipids, and obesity are associated with retinopathy: the Hoorn study. Diabetes Care. 2002;25(8):1320–5.

    Article  PubMed  Google Scholar 

  26. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61.

    Article  CAS  PubMed  Google Scholar 

  27. Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP. Metabolic control and diabetic retinopathy. Curr Diabetes Rev. 2009;5(1):3–7.

    Article  CAS  PubMed  Google Scholar 

  28. Jaumdally RJ, Goon PK, Varma C, Blann AD, Lip GY. Effects of atorvastatin on circulating CD34+/CD133+/CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus. J Intern Med. 2010;267(4):385–93.

    Article  CAS  PubMed  Google Scholar 

  29. Dworacka M, Krzyzagorska E, Wesolowska A, Borowska M, Iskakova S, Dworacki G. Statins in low doses reduce VEGF and bFGF serum levels in patients with type 2 diabetes mellitus. Pharmacology. 2014;93(1–2):32–8.

    Article  CAS  PubMed  Google Scholar 

  30. •• Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985, 103(12):1796–1806. Landmark study first showing the benefit of laser for diabetic retiopathy.

  31. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophthalmology 1978, 85(1):82–106.

  32. Photocoagulation treatment of proliferative diabetic retinopathy: relationship of adverse treatment effects to retinopathy severity. Diabetic retinopathy study report no. 5. Dev Ophthalmol 1981, 2:248–261.

  33. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology 1981, 88(7):583–600.

  34. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14. The Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin 1987, 27(4):239–253.

  35. Oh IK, Kim SW, Oh J, Lee TS, Huh K. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Curr Eye Res. 2010;35(12):1116–27.

    Article  CAS  PubMed  Google Scholar 

  36. Stefansson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol. 2006;51(4):364–80.

    Article  PubMed  Google Scholar 

  37. Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005;353(8):839–41.

    Article  CAS  PubMed  Google Scholar 

  38. Bressler NM, Beck RW, Ferris 3rd FL. Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med. 2011;365(16):1520–6.

    Article  CAS  PubMed  Google Scholar 

  39. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22(1):1–29.

    Article  CAS  PubMed  Google Scholar 

  40. Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39(5):469–78.

    CAS  PubMed  Google Scholar 

  41. Diabetic Retinopathy Clinical Research N, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077 e1035.

    Article  Google Scholar 

  42. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris 3rd FL, Friedman SM, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609–14.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Diabetic Retinopathy Clinical Research N, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL, 3rd, Glassman AR, Maturi RK, Melia M: Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012, 119(11):2312–2318.

  44. • Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–54. Pivotal phase III trial showing benefit of aflibercept for DME and DR in DME patients.

    Article  PubMed  Google Scholar 

  45. • Nguyen QD, Brown DM, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801. Pivotal phase III trial showing benefit of ranibizumab for DME and DR in DME patients.

    Article  PubMed  Google Scholar 

  46. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145–52.

    Article  CAS  PubMed  Google Scholar 

  47. Sultan MB, Zhou D, Loftus J, Dombi T, Ice KS, Macugen Study G. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology. 2011;118(6):1107–18.

    Article  PubMed  Google Scholar 

  48. Adamis AP, Altaweel M, Bressler NM, Cunningham Jr ET, Davis MD, Goldbaum M, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology. 2006;113(1):23–8.

    Article  PubMed  Google Scholar 

  49. Giuliari GP, Guel DA, Gonzalez VH. Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema. Curr Diabetes Rev. 2009;5(1):33–8.

    Article  CAS  PubMed  Google Scholar 

  50. Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007;27(9):1187–95.

    Article  PubMed  Google Scholar 

  51. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology. 2009;116(6):1142–50.

    Article  PubMed  Google Scholar 

  52. Solaiman KA, Diab MM, Abo-Elenin M. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Retina. 2010;30(10):1638–45.

    Article  PubMed  Google Scholar 

  53. Diabetic Retinopathy Clinical Research N, Diabetic Retinopathy Clinical Research N, Scott IU, Edwards AR, Beck RW, Bressler NM, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860–7.

    Article  Google Scholar 

  54. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–9.

    Article  CAS  PubMed  Google Scholar 

  55. Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology. 2009;116(8):1488–97. 1497 e1481.

    Article  PubMed  Google Scholar 

  56. Ishikawa K, Honda S, Tsukahara Y, Negi A. Preferable use of intravitreal bevacizumab as a pretreatment of vitrectomy for severe proliferative diabetic retinopathy. Eye. 2009;23(1):108–11.

    Article  CAS  PubMed  Google Scholar 

  57. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275–8.

    Article  PubMed  Google Scholar 

  58. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695 e1-15.

    Article  PubMed  Google Scholar 

  59. Thew M. Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin). Clin Exp Optom. 2009;92(1):34–7.

    Article  PubMed  Google Scholar 

  60. Minnella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol. 2008;86(6):683–7.

    Article  PubMed  Google Scholar 

  61. Schmidinger G, Maar N, Bolz M, Scholda C, Schmidt-Erfurth U. Repeated intravitreal bevacizumab (Avastin®) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol. 2011;89(1):76–81.

    Article  CAS  PubMed  Google Scholar 

  62. Mirshahi A, Roohipoor R, Lashay A, Mohammadi SF, Abdoallahi A, Faghihi H. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol. 2008;18(2):263–9.

    CAS  PubMed  Google Scholar 

  63. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293(4):865–81.

    Article  CAS  PubMed  Google Scholar 

  64. • Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, Feiner L, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–22. Pivotal phase III trial showing benefit of ranibizumab for DME and DR in DME patients.

    Article  PubMed  Google Scholar 

  65. Diabetic Retinopathy Clinical Research N. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131(3):283–93.

    Article  Google Scholar 

  66. Writing Committee for the Diabetic Retinopathy Clinical Research N, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–46.

    Article  Google Scholar 

  67. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. •• Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. New England J Med. 2015;372(13):1193–203. Comparative effectiveness trial evaluating efficacy of 3 available anti-VEGF agents in the treatment of DME.

    Article  CAS  Google Scholar 

  69. •• Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology. 2016;123(6):1351–9. Comparative effectiveness trial evaluating efficacy of 3 available anti-VEGF agents in the treatment of DME.

    Article  PubMed  Google Scholar 

  70. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6(8):465–77.

    Article  CAS  PubMed  Google Scholar 

  71. Investigators IS, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399–411.

    Article  Google Scholar 

  72. Zehetner C, Kirchmair R, Huber S, Kralinger MT, Kieselbach GF. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97(4):454–9.

    Article  PubMed  Google Scholar 

  73. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636–41.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol. 2014;158(4):738–44. e731.

    Article  CAS  PubMed  Google Scholar 

  75. Virgili G, Parravano M, Menchini F, Brunetti M. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev. 2012;12:CD007419.

    PubMed  Google Scholar 

  76. Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol. 2016;134(1):21–9.

    Article  PubMed  Google Scholar 

  77. Avery RL. What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned? Br J Ophthalmol. 2014;98 Suppl 1:i7–10.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. California Retina Consultants and Research Foundation, 525 East Micheltorena Street, Suite A, Santa Barbara, CA, 93103, USA

    Dilsher S. Dhoot & Robert L. Avery

Authors
  1. Dilsher S. Dhoot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert L. Avery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dilsher S. Dhoot.

Ethics declarations

Conflict of Interest

Dilsher S. Dhoot reports personal fees from Alimera, personal fees from Santen, grants and personal fees from Regeneron, and grants from Genentech.

Robert L. Avery reports personal fees from Alcon, grants and personal fees from Allergan, personal fees from Bausch and Lomb, personal fees from Alimera, grants, personal fees and non-financial support from Genentech, personal fees and other from Novartis, grants, personal fees and other from Regeneron, and personal fees from Regenxbio, personal fees and other from Replenish. In addition, Dr. Avery has a patent Intravitreal Drug Delivery with royalties paid to Replenish.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Microvascular Complications—Retinopathy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhoot, D.S., Avery, R.L. Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy. Curr Diab Rep 16, 122 (2016). https://doi.org/10.1007/s11892-016-0825-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11892-016-0825-4

Keywords

Search

Navigation